BioCardia, Inc. Common Stock (BCDA)

Price$0.92

Value ScoreD

Growth ScoreF

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-43.27%

Price vs S&P 500 (4W)-21.19%

VGM Score21.27

Market Capitalization$10.58M

All Metrics

Book Value / Share (Quarterly)$0.08

P/TBV (Annual)51.82x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-61.55%

Cash Flow / Share (Quarterly)$-0.68

Price vs S&P 500 (YTD)-36.53%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-1985.85%

EPS (TTM)$-0.80

10-Day Avg Trading Volume0.14M

EPS Excl Extra (TTM)$-0.80

Revenue Growth (5Y)-39.41%

EPS (Annual)$-1.23

ROI (Annual)-919.33%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-5649.05%

Cash / Share (Quarterly)$0.09

ROA (Last FY)-241.08%

EBITD / Share (TTM)$-0.71

ROE (5Y Avg)-462.40%

Operating Margin (TTM)-1997.45%

Cash Flow / Share (Annual)$-0.69

P/B Ratio11.82x

P/B Ratio (Quarterly)14.82x

Net Income / Employee (Annual)$-484,000

EV / Revenue (TTM)22.34x

Net Interest Coverage (TTM)-2.48x

ROA (TTM)-261.66%

EV / EBITDA (TTM)4.11x

EPS Incl Extra (Annual)$-1.23

Current Ratio (Annual)1.12x

Quick Ratio (Quarterly)0.35x

3-Month Avg Trading Volume0.13M

52-Week Price Return-57.04%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.75

P/S Ratio (Annual)182.39x

Asset Turnover (Annual)0.02x

52-Week High$2.45

Operating Margin (5Y Avg)-5673.79%

EPS Excl Extra (Annual)$-1.23

CapEx CAGR (5Y)-25.25%

Tangible BV CAGR (5Y)-15.15%

26-Week Price Return-27.34%

Quick Ratio (Annual)1.03x

13-Week Price Return-25.00%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.41x

Enterprise Value$9.63M

Revenue / Share Growth (5Y)-30.04%

Asset Turnover (TTM)0.14x

Book Value / Share Growth (5Y)-24.84%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)5.14x

Pretax Margin (Annual)-13700.00%

Cash / Share (Annual)$0.23

3-Month Return Std Dev51.94%

Gross Margin (5Y Avg)43.27%

Net Income / Employee (TTM)$-370,100

ROE (Last FY)-919.33%

Net Interest Coverage (Annual)-93.75x

EPS Basic Excl Extra (Annual)$-1.23

P/FCF (TTM)32.06x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.80

Receivables Turnover (Annual)0.00x

ROI (TTM)-221.68%

P/S Ratio (TTM)24.54x

Pretax Margin (5Y Avg)-5649.05%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.03

Price vs S&P 500 (52W)-85.25%

Year-to-Date Return-25.60%

5-Day Price Return-2.62%

EPS Normalized (Annual)$-1.23

ROA (5Y Avg)-208.75%

Net Profit Margin (Annual)-13700.00%

Month-to-Date Return-18.42%

Cash Flow / Share (TTM)$-0.62

EBITD / Share (Annual)$-1.24

Operating Margin (Annual)-13794.83%

ROI (5Y Avg)-462.40%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-0.80

P/TBV (Quarterly)24.70x

P/B Ratio (Annual)14.82x

Inventory Turnover (TTM)12.00x

Pretax Margin (TTM)-1985.85%

Book Value / Share (Annual)$0.08

Price vs S&P 500 (13W)-34.75%

Beta0.50x

P/FCF (Annual)32.06x

Revenue / Share (TTM)$0.00

ROE (TTM)-221.68%

52-Week Low$0.84

vGradeD

gGradeF

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.21est. -0.17

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
BCDABioCardia, Inc. Common Stock	D	F	D	$0.92
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

BioCardia is a clinical-stage company developing cell-based therapeutics for cardiovascular and pulmonary diseases with unmet medical needs. Its CardiAMP platform delivers autologous mononuclear cells derived from bone marrow to treat ischemic heart failure with reduced ejection fraction and refractory angina, while its CardiALLO platform uses off-the-shelf allogeneic mesenchymal stem cells for ischemic heart failure and acute respiratory distress syndrome. CardiALLO is currently enrolling patients in clinical trials.